GLP1R and metabolic syndrome: Current guidelines additionally recommend the use of novel agents, such as monoclonal antibodies directed against dyslipidemia (e.g., alirocumab, evolocumab) and glucagon-like peptide-1 (GLP-1) receptor agonists [31].